Insights into the clinical management of the syndrome of supine hypertension--orthostatic hypotension (SH-OH): the Irish Longitudinal Study on Ageing (TILDA). by Romero-Ortuno, Roman et al.
Romero-Ortuno et al. BMC Geriatrics 2013, 13:73
http://www.biomedcentral.com/1471-2318/13/73RESEARCH ARTICLE Open AccessInsights into the clinical management of the
syndrome of supine hypertension – orthostatic
hypotension (SH-OH): The Irish Longitudinal
Study on Ageing (TILDA)
Roman Romero-Ortuno*, Matthew DL O’Connell, Ciaran Finucane, Christopher Soraghan, Chie Wei Fan
and Rose Anne KennyAbstract
Background: Our previously proposed morphological classification of orthostatic hypotension (MOH) is an approach
to the definition of three typical orthostatic hemodynamic patterns using non-invasive beat-to-beat monitoring.
In particular, the MOH pattern of large drop/non-recovery (MOH-3) resembles the syndrome of supine hypertension–
orthostatic hypotension (SH-OH), which is a treatment challenge for clinicians. The aim of this study was to
characterise MOH-3 in the first wave of The Irish Longitudinal Study of Ageing (TILDA), with particular attention to
concurrent symptoms of orthostatic intolerance (OI), prescribed medications and association with history of faints
and blackouts.
Methods: The study included all TILDA wave 1 participants who had a Finometer® active stand. Automatic data
signal checks were carried out to ensure that active stand data were of sufficient quality. Characterisation variables
included demographics, cardiovascular and neurological medications (WHO-ATC), and self-reported information on
comorbidities and disability. Multivariable statistics consisted of logistic regression models.
Results: Of the 4,467 cases, 1,456 (33%) were assigned to MOH-1 (small drop, overshoot), 2,230 (50%) to MOH-2
(medium drop, slower but full recovery), and 781 (18%) to MOH-3 (large drop, non-recovery). In the logistic regression
model to predict MOH-3, statistically significant factors included being on antidepressants (OR = 1.99, 95%
CI: 1.50 – 2.64, P < 0.001) and beta blockers (OR = 1.60, 95% CI: 1.26 – 2.04, P < 0.001). MOH-3 was an independent
predictor of OI after full adjustment (OR = 1.47, 95% CI: 1.25 – 1.73, P < 0.001), together with being on hypnotics or
sedatives (OR = 1.83, 95% CI: 1.31 – 2.54, P < 0.001). In addition, OI was an independent predictor of history of
falls/blackouts after full adjustment (OR = 1.27, 95% CI: 1.09 – 1.48, P = 0.003).
Conclusions: Antidepressants and beta blockers were independently associated with MOH-3, and should be used
judiciously in older patients with SH-OH. Hypnotics and sedatives may add to the OI effect of MOH-3. Several trials
have demonstrated the benefits of treating older hypertensive patients with cardiovascular medications that were
not associated with adverse outcomes in our study. Therefore, the evidence of benefit does not necessarily have to
conflict with the evidence of potential harm.
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Orthostatic hypotension (OH) is generally defined as a
drop in blood pressure on standing, which in a given
subject is regarded as abnormal purely on the basis of its
magnitude. As such, OH is a clinical sign and may be
symptomatic or asymptomatic [1].
Orthostatic blood pressure changes can be measured
by different methods. Most commonly, clinicians use the
auscultatory or oscillometric method with sphygmoma-
nometer [2]. As applied to the latter methods, OH is de-
fined by consensus as a sustained reduction of systolic
blood pressure (SBP) of at least 20 mmHg or diastolic
blood pressure (DBP) of 10 mmHg within 3 minutes of
standing [1]. Many clinicians also measure orthostatic
hemodynamic changes with non-invasive beat-to-beat
finger arterial blood pressure monitors; however, in the
latter case the consensus definition of OH may lack cli-
nical relevance [3,4] and there are no internationally
agreed cut-offs for the definition of OH.
OH is an independent cardiovascular risk factor and
may be practically estimated by systolic reaction only
[5]. It is recognised that elevated SBP prior to a standing
manoeuvre is directly associated with the magnitude of
the SBP drop [6], to the extent that the current consen-
sus definition of OH requires an SBP drop of at least
30 mmHg in patients with supine hypertension [1]. The
clinically recognised syndrome of supine hypertension
and orthostatic hypotension (SH-OH) poses a particular
therapeutic dilemma, as treatment of one aspect of the
condition may worsen the other [7]. Indeed, in the treat-
ment of combined hypertension and OH in older adults,
more questions than answers still remain [8], and little is
known on the influences of cardiovascular and neuro-
logical medications on this syndrome.
Although most patients with OH are asymptomatic or
have few non-specific symptoms [9], a marked orthostatic
blood pressure drop may cause symptoms of orthostatic
intolerance (OI) such as dizziness, light-headedness, and/
or loss or near-loss of consciousness [10,11]. These symp-
toms are attributed to hypoperfusion of the central ner-
vous system during orthostasis [12]. OI symptoms may
correlate with the lowest blood pressure point reached
(i.e. nadir), with the magnitude of blood pressure drop
(i.e. delta), or with the rate of blood pressure recovery
[13,14]. However, OI may also be caused by conditions
other than blood pressure changes, such as vestibular
[15,16] or psychosomatic [17] disorders. Indeed, OI is a
heterogeneous syndrome [18,19].
It has been suggested that postural symptoms (i.e. OI)
correlate much more strongly with (pre-)syncope and falls
than does OH (i.e. the isolated blood pressure drop sign)
per se [20,21]. In other words, if OH triggers OI symp-
toms, then syncope is more likely. However, in many real-
life situations the latter theoretical sequence is interrupted,as marked OH can be asymptomatic [22,23] and not all
instances of OI result in syncope [18,24].
In a previous investigation, a morphological classification
of OH (MOH) was proposed [25] as an approach to the
measurement of three known [26-28] orthostatic hemo-
dynamic patterns using non-invasive beat-to-beat finger
arterial blood pressure monitoring. In that study, a gradi-
ent of OI was identified across morphological blood pres-
sure patterns: 17.9% in the small drop/fast over-recovery
(MOH-1), 27.5% in the medium drop/slow recovery
(MOH-2) and 44.6% in the large drop/non-recovery group
(MOH-3) (P < 0.001). We also showed a gradient of base-
line SBP across MOH groups, suggesting that MOH-3 is,
in fact, a syndrome of SH-OH. To date, there had been no
studies of the SH-OH syndrome using non-invasive beat-
to-beat finger arterial blood pressure monitoring.
In view of the above, the aims of the present study were:
(1) to replicate the MOH patterns in a large, population-
based sample such as the first wave of The Irish Longitu-
dinal Study on Ageing (TILDA, http://www.tcd.ie/tilda),
with especial attention to the MOH-3 pattern as a beat-to
-beat analogue of SH-OH; (2) to characterise the MOH-3
group with especial attention to associations with cardio-
vascular and neurological medications, concurrent OI,
and history of fainting; (3) to identify predictors of MOH-
3 response in the presence of potential confounders; and
(4) to assess the effect of MOH-3 towards OI, and the ef-
fect of MOH-3 and OI towards fainting history, in the
presence of confounders. The latter can be seen as a
cross-sectional evaluation of the above-mentioned three
pathophysiological steps (OH → OI → fainting). A com-
prehensive investigation of factors associated with each of
those three steps has not been conducted to date but
would be helpful in order to gain insights into potentially
modifiable factors to prevent OH and OI-related faints,
particularly in relation to association with prescribed me-
dications in the SH-OH syndrome. The identified factors
will then be investigated longitudinally in TILDA.
Methods
Setting
The Irish Longitudinal Study on Ageing (TILDA, http://
www.tcd.ie/tilda/) is a large prospective cohort study of
the social, economic, and health circumstances of
community-dwelling older people in Ireland. This study
is based on the first wave of data, which was collected
between October 2009 and July 2011. The sampling
frame is the Irish Geodirectory, a listing of all residential
addresses in the Republic of Ireland. A clustered sample
of addresses was chosen, and household residents aged
50 and older and their spouses/partners (of any age)
were eligible to participate. The household response rate
was 62.0%. In the present study, the analytic sample
consisted of those aged ≥ 50 from TILDA wave 1.
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[29,30]. There were three parts to data collection: a
computer-assisted personal interview that included de-
tailed questions on sociodemographic characteristics,
wealth, health, lifestyle, social support and participation,
use of health and social care, and attitudes toward aging; a
self-completion questionnaire; and a health assessment
that research nurses performed. Health assessments were
conducted in a health centre or in the homes of partici-
pants; however, only the centre-based assessments in-
cluded detailed measurements and novel technologies such
as beat-to-beat finger arterial blood pressure monitors [31].
Ethics and consent
Ethical approval was obtained from the Trinity College
Dublin Research Ethics Committee, and all participants
provided written informed consent.
Active stand protocol
Subjects underwent a lying-to-standing orthostatic test
(active stand) with non-invasive beat-to-beat blood pres-
sure monitoring using digital photoplethysmography
(Finometer® MIDI device, Finapres Medical Systems BV,
Amsterdam, The Netherlands, www.finapres.com).
An appropriate cuff size was applied to the finger as
recommended by the manufacturer [32]. Prior to standing,
subjects were resting in the supine position for 10 minutes.
The active stand protocol included the use of the auto-
matic physiocal function (physiologic calibration that
calibrates the finger arterial size at which finger cuff air
pressure equals finger arterial blood pressure). We
aimed at the beat interval between physiocals being 30
beats or higher before the start of the active stand. Just
prior to standing, the physiocal was switched off to as-
certain a continuous recording during the orthostatic
blood pressure changes, and remained switched off until
the end of the test.
The height correction unit (HCU) of the Finometer®
was zeroed and implemented as per manufacturer’s
specifications [32], and was used to compensate for
hydrostatic pressure changes on standing. After the ten
minutes of supine rest the subjects were asked to stand,
unaided, in a timely manner. After standing, systolic,
diastolic blood pressure, and heart rate were monitored
for three minutes. Throughout the recording subjects
stood motionless and in silence with the monitored arm
resting extended by the side. Immediately after the test,
subjects were asked to report whether they had felt any
symptoms of dizziness, light-headedness or unsteadiness
(OI: yes or no).
Active stand data pre-processing
Active stand data analysis required a number of steps in-
cluding: 1) data quality screening and artefact rejection;2) pre-processing and filtering; and 3) blood pressure
waveform feature extraction. Data were imported and
processed in Matlab® R2011b. Data records where the
HCU had not been properly applied (e.g. sensor fell off
during the recording, was zero throughout, contained
significant noise, or was inverted due to incorrect place-
ment) were removed from the analysis.
Additional checks were carried out on the data such as
ensuring data met the requirement of a minimum length
of stand (≥ 90 seconds). A further check examined the
total noise in the baseline and stand sections. For this,
each record was divided into two sections; baseline pre-
stand (baseline) and standing activity (stand) demarked by
times before and after the stand. Each of the sections -
baseline and stand - was scored in terms of artefact pres-
ence separately. The total number of beats within the
baseline and stand sections was counted. The proportion
of total time containing significant motion artefact as a
fraction of the total signal time were used to quantify the
amount of noise in the signal using a validated automated
algorithm [33,34]. Signals with significant artefact were
rejected from the analysis as per pre-defined criteria.
For the final dataset to be used in the analysis, beat-to-
beat values were averaged according to the 5-second ave-
rages method described by van der Velde et al. [35], in
order to filter any remaining noise. Following this, features
were extracted for each of these records.
Finometer® features
The following measures were recorded:
 Baseline systolic (SBP), diastolic blood pressure (DPB),
and heart rate (HR): defined as the mean value in
the time interval −60 seconds to −30 seconds prior
to standing.
 SPB, DBP and HR at the lowest blood pressure value
after standing (i.e. nadir values, which are generally
achieved within 15 seconds after standing [36]).
 SPB, DBP and HR at 30 seconds post-stand.
 SPB, DBP and HR at 60 seconds post-stand.
 SPB, DBP and HR at 90 seconds post-stand.
 SPB, DBP and HR at 110 seconds post-stand.
 Delta (ΔSBP, ΔDBP and ΔHR) was defined as the
difference between the respective baselines and nadirs.
 We also computed the percentage of SBP recovery
(with respect to baseline) by 30 seconds, 60 seconds,
and 110 seconds after the stand.
Characterisation variables
 Demographics: age, sex.
 Orthostatic intolerance (OI): self-reported symptoms
of dizziness, light-headedness or unsteadiness during
the active stand (yes or no).
Romero-Ortuno et al. BMC Geriatrics 2013, 13:73 Page 4 of 14
http://www.biomedcentral.com/1471-2318/13/73 Ever had a blackout or fainted: yes or no.
 Medications, based on the WHO Anatomical
Therapeutic Chemical (ATC) classification system
(http://www.whocc.no/atc_ddd_index/):
○ Cardiovascular medications:
▪ C01A: cardiac glycosides.
▪ C01B: antiarrhythmics, class I and III.
▪ C07A: beta blocking agents.
▪ C03: diuretics.
▪ C09A: ACE inhibitors, plain.
▪ C09C: angiotensin II antagonists, plain.
▪ C08C: selective calcium channel blockers with
mainly vascular effects.
▪ C08D: selective calcium channel blockers with
direct cardiac effects.
▪ C02C: antiadrenergic agents, peripherally
acting.
▪ C01D: vasodilators used in cardiac diseases.
▪ C04A: peripheral vasodilators.
○ Neurological medications:
▪ N03A: antiepileptics.
▪ N05A: antipsychotics.
▪ N05B: anxiolytics.
▪ N05C: hypnotics and sedatives.
▪ N06A: antidepressants.
○ Polypharmacy was defined as the simultaneous
use of 5 or more medications.
 Comorbidities (self-reported):
○ Hypertension.
○ Angina.
○ Heart attack.
○ Heart failure.
○ Diabetes.
○ Stroke.
○ Transient ischaemic attack (TIA).
○ Abnormal heart rhythm.
○ Parkinson’s disease.
○ Three or more chronic diseases.
 Disability (self-reported): any disability from the list
of Independent Activities of Daily Living (IADL).
 Cognition: Mini-Mental State Examination (MMSE)
score.
Statistics
All statistical analyses were performed with SPSS (ver-
sion 18). Descriptives for dichotomous variables were
given as percentages (%). Continuous variables were de-
scribed as mean with standard deviation (SD).
To classify the sample into MOH groups we used, as
before [25], an automatic K-means Cluster Analysis pro-
cedure, which assigns cases to a fixed number of groups
(clusters) whose characteristics are not yet known but
are based on a set of specified (clustering) variables. We
chose three (k = 3) as the number of clusters becausethree were the previously described [26-28] orthostatic
hemodynamic patterns. There was no statistical process
to arrive at k = 3.
The clustering variables (i.e. ΔSBP and % of Baseline
SBP at 30, 60 and 110 s) were chosen as key morphological
descriptors of the beat-to-beat orthostatic blood pressure
response that we intended to model. The influence of out-
liers on the K-means cluster analysis was minimised by
the pre-processing and data cleaning steps as outlined
above.
In the K-means analysis, the clustering variables were
entered unstandardised. It was decided not to standard-
ise the clustering variables as some have argued that
standardisation (z-scores specifically) can result in mis-
leading conclusions when true group structure is present
[37]. The final cluster membership variable was saved to
the dataset.
To compare baseline characteristics between those with
and without MOH data, we used the t-test or Mann–
Whitney U test (as appropriate) for continuous variables,
and the Chi-square test for count data.
To test for a linear trend (i.e. gradient) across MOH
clusters, we used the Chi-square for trend for dichotom-
ous variables and the Spearman’s rank correlation coeffi-
cient for continuous variables.
Multivariable analyses were based on binary logistic
regression (forward conditional procedure). This step-
wise method of variable selection involves entry testing
based on the significance of the score statistic, and re-
moval testing based on the probability of a likelihood-
ratio statistic based on conditional parameter estimates.
The significance level for entry into the model was set at
P < 0.05 and for removal was set at P < 0.1.
Multicollinearity diagnostics (tolerance and variance in-
flation factors: VIF) were checked. The multivariable
models were repeated in the subsample of those aged ≥70
in order to explore whether the overall findings also ap-
plied to those of more advanced age.
For the purpose of the discussion, and given the elevated
number of characterisation variables used, we focused on
the most statistically significant associations (i.e. P < 0.01).
Results
Of the 8,175 participants aged 50 and over in the first
wave of TILDA, 5,037 (62%) had a Health Centre As-
sessment. Amongst the latter, 4,919 (98%) completed the
active stand test. Active stand data were deemed of suffi-
cient quality for analysis in 4,475 participants (91% of
active stands). Complete data for defining the MOH
groups was available for 4,467 participants. The flow-
chart of participants is shown in Figure 1.
Table 1 compares characteristics of Health Centre parti-
cipants with (N = 4,467) and without (N = 570) MOH data.
Those without MOH data were older (mean age 65 vs.
Figure 1 Flowchart of participants.
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vs. 134 mmHg, P < 0.001), were taking a higher number
of medications (mean 3 vs. 2, P < 0.001), had higher
burden of cardiovascular disease (at least 1: 70% vs. 62%,
P < 0.001) and higher disability burden (at least 1 IADL
disability: 10% vs. 4%, P < 0.001).
In the K-means analysis on N = 4,467, all clustering vari-
ables significantly contributed to the solution (P < 0.001).
Table 2 shows the characteristics of the three morpho-
logical groups and Figure 2 shows their hemodynamic
profiles. Of the 4,467 cases assigned to clusters, 1,456
(33%) were assigned to MOH-1 (characterised by a small
drop and overshoot), 2,230 (50%) to MOH-2 (characterised
by a medium drop and slower but full recovery), and 781
(18%) to MOH-3 (characterised by a large drop and in-
complete recovery).
OI and fainting history (Table 2)
Across MOH groups, there was a significant gradient in
OI and a non-significant gradient in history of faints/
blackouts, in the expected direction (P < 0.001 and P =
0.065, respectively).
MOH groups: other gradients (Table 2)
Age-wise, the mean age of participants in MOH-3 was
64 years, while in MOH-1 and MOH-2 it was 61 years.Table 1 Comparison of Health Centre participants with and w
Has MOH groups (N = 4
Age: mean (SD) 61.6 (8.3)
Seated* SBP: mean (SD) 134.3 (19.4)
Seated* DBP: mean (SD) 82.3 (11.1)
Number of medications: mean (SD) 2.3 (2.5)
Any cardiovascular disease: count (%) 2,772 (62.1)
Any IADL disability: count (%) 172 (3.9)
a t-test; b Mann Whitney U test; c Chi-square test.
* Seated blood pressure was measured with sphygmomanometer.There was an increasing gradient of female sex across
MOH clusters (49%, 53% and 64%, respectively).
Twenty-one percent of participants in MOH-3 were on
polypharmacy, as opposed to 17% of participants in
MOH-1 and MOH-2. Sixteen percent of MOH-3 partici-
pants were on beta blockers, compared to 10% in MOH-1
and MOH-2.
Across MOH groups, there was an increasing burden
of antidepressants (P < 0.001). There was also an in-
creasing burden of peripherally acting antiadrenergic
agents (e.g. alpha blockers) (P = 0.004) (Table 2).
As regards comorbidity burden, 35% of participants in
MOH-3 had history of hypertension, compared to 32%
and 32% of MOH-1 and MOH-2 participants, respec-
tively. Twenty-seven percent of MOH-3 participants had
three or more chronic diseases, compared to 23% and
24% of MOH-1 and MOH-2 participants, respectively.
There were increasing gradients of history of angina and
abnormal heart rhythm across MOH clusters, and a de-
creasing gradient in diabetes. None of these trends
reached statistical significance. There was a non signifi-
cant gradient of increasing IADL disability across clus-
ters (P = 0.058) (Table 2).
In the multivariable binary logistic regression model to
predict MOH-3 membership (Table 3), the statistically
significant factors were: antidepressants (OR = 1.99, 95%
CI: 1.50 – 2.64, P < 0.001), female sex (OR = 1.73, 95%
CI: 1.46 – 2.04, P < 0.001), beta blockers (OR = 1.60, 95%
CI: 1.26 – 2.04, P < 0.001), and age (OR = 1.03, 95% CI:
1.03 – 1.04, P < 0.001). In addition, those on peripheral
calcium channel blockers were less likely to have a MOH-
3 response (OR = 0.68, 95% CI: 0.49 – 0.94, P < 0.001). In
the subsample of those aged 70 or more, antidepressants,
sex, beta blockers, age and peripheral calcium channel
blockers still had 95% CIs not including 1 (Table 3).
In the multivariable binary logistic regression model to
predict OI during active stand (Table 4), the statistically
significant factors were: hypnotics and sedatives (OR =
1.83, 95% CI: 1.31 – 2.54, P < 0.001), MOH-3 (OR = 1.47,
95% CI: 1.25 – 1.73, P < 0.001), and history of heart attack
(OR = 1.59, 95% CI: 1.16 – 2.19, P = 0.004). In addition,
advancing age (OR = 0.98, 95% CI: 0.98 – 0.99, P < 0.001)ithout MOH data
,467) Missing MOH groups (N = 570) P
64.5 (9.4) <0.001a
137.4 (20.0) <0.001a
82.5 (11.5) 0.67a
2.8 (2.9) <0.001b
403 (70.1) <0.001c
58 (10.1) <0.001c
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were associated with less OI during active stand. In the
subsample of those aged 70 or more, being on antiepilep-
tics and having 3 or more chronic diseases seemed to be
associated with greater OI, while peripheral calcium chan-
nel blockers seemed protective (Table 4).
In the multivariable binary logistic regression model to
predict history of blackouts or faints (Table 5), statistically
significant factors were: antiepileptics (OR = 2.39, 95%
CI: 1.57 – 3.63, P < 0.001), history of abnormal heart
rhythm (OR = 1.95, 95% CI: 1.49 – 2.53, P < 0.001), history
of TIA (OR = 1.93, 95% CI: 1.15 – 3.25, P = 0.013), female
sex (OR = 1.35, 95% CI: 1.16 – 1.57, P < 0.001), antidepres-
sants (OR = 1.62, 95% CI: 1.22 – 2.15, P = 0.001),
polypharmacy (OR = 1.37, 95% CI: 1.12 – 1.68, P = 0.002),
and OI during active stand (OR = 1.27, 95% CI: 1.09 – 1.48,
P = 0.003). In the subsample of those aged 70 or more,
antiepileptics, history of abnormal heart rhythm, female
sex and polypharmacy were directly associated with his-
tory of blackouts or faints.
In all multivariable models, all VIF were less than 2,
excluding significant multicollinearity.
Discussion
In the present study, we replicated and characterised the
MOH groups and assessed the association of MOH-3
(postulated as a beat-to-beat equivalent of the SH-OH
syndrome) on concurrent OI and fainting history. The ad-
vantage of the present study is that it is based on a large
population-based sample, as opposed to the previous
study [25], which was based on a small convenience sam-
ple. The aim was to identify potentially modifiable factors
to prevent OH and OI-related faints, particularly in rela-
tion to association with prescribed medications, and in-
form further longitudinal studies in TILDA. Naturally, in
view of the observational and cross-sectional nature of the
study, results need to be interpreted with caution and rep-
resent ‘insights’ rather than confirmed signals.
Results highlighted the association of MOH-3 with non-
modifiable risk factors such as age and sex, even in the
subsample of those aged 70 or more. Consistent with pre-
vious literature, advancing age is associated with hyperten-
sion [38] and greater orthostatic blood pressure drops
[39,40]. There are also known differences in postural auto-
nomic modulation between men and women, which might
make women less able to compensate for drops in blood
pressure in response to positional changes [41].
In terms of potentially modifiable factors, our findings
highlight the important influence of certain types of medi-
cations (particularly antidepressants and beta blockers)
in contributing to an SH-OH response (even in those
aged ≥70), which may potentially lead to clinically adverse
consequences (e.g. complaints of OI). In particular, results
strengthen the hypothesis on the relationship between OHand antidepressant pharmacotherapy [42], and also be-
tween depressive symptoms and impaired orthostatic
blood pressure response. It is known that OH and OI are
more frequent in depressed older adults [43], and recent
studies have found evidence for an association between
the degree of orthostatic SBP drop and brain white matter
hyperintensities volume in late-life depression [44,45].
Our results also highlight the association between beta
blockers and an impaired orthostatic blood pressure re-
sponse. The higher burden of beta blockers in MOH-3
subjects is consistent with their lower baseline heart rate
and poorer orthostatic heart rate response (Table 2).
Beta receptors have been implicated in the pathophysi-
ology of OH [46]; indeed, a known primary autonomi-
cally mediated mechanism for maintenance of mean
arterial pressure and orthostatic tolerance in healthy
subjects is beta adrenergic-induced tachycardia [47]. Our
results agree with previous observations that the pressor
effects of beta blockers on standing blood pressure may
be harmful for older patients with OH [48].
An interesting insight is the potential protective effect of
peripheral calcium channel blocker (CCB) medications
against MOH-3 (also present in the older subgroup),
which is supported by the literature. For example, in a pre-
vious study, the peripheral CCB Nilvadipine did not aggra-
vate OH in a sample of patients with Alzheimer’s disease,
despite significant reduction in the SBP of treated patients
[49]. In another study in hypertensive patients, the periph-
eral CCB Cilnidipine showed significant decreases in
blood pressure without adverse OH effects [50]. Further-
more, a study comparing the influences of anti-anginal
drugs on cardiovascular responsiveness to orthostasis
found that a dihydropyridine CCB influenced the latter
less than a mononitrate or a beta-blocker [51].
On bivariate analyses, we found an increasing burden
of peripherally acting antiadrenergic agents (e.g. alpha
blockers) across MOH groups. It is likely that the num-
ber of patients on alpha blockers was too small to detect
an independent effect in multivariable analyses. Yet, the
alpha(1)-adrenergic receptor pathway is known to be
critical in the recovery from initial OH to prevent cere-
bral hypoperfusion and ultimately syncope [52], so the
clinical relevance of alpha blockers in the SH-OH syn-
drome might be significant.
Our results support previous findings that OI is a
wider, more complex syndrome than the mere sign of
having an impaired orthostatic hemodynamic response
[19]. In the full sample, MOH-3 was as an independent
predictor of OI, but the latter was not the case in the
older subsample. In terms of non-modifiable risk factors,
and in the full sample, OI was less likely to be reported
by females and at advancing age. Again, these age and
sex effects merit further investigation but, since they are
not modifiable, were not the focus of our study. Previous
Table 2 MOH clusters characterisation
MOH-1 MOH-2 MOH-3 P
Small drop,
overshoot
Medium drop,
just recovery
Large drop,
non-recovery
N = 1,456 N = 2,230 N = 781
Systolic blood pressure (SBP)
Baseline SBP (mmHg) 130.4 (20.7) 137.2 (21.3) 144.9 (24.9) <0.001Σ
Δ SBP (mmHg) −24.1 (10.8) −40.2 (9.9) −64.8 (15.2) <0.001Σ
Nadir SBP (mmHg) 106.3 (22.0) 97.0 (22.1) 80.1 (24.5) <0.001Σ
SBP by 30 s (mmHg) 143.1 (22.9) 133.8 (23.0) 122.9 (28.7) <0.001Σ
SBP by 30 s (% baseline) 110.0 (8.1) 97.5 (6.6) 84.5 (11.4) <0.001Σ
SBP by 60 s (mmHg) 142.5 (23.4) 134.0 (23.2) 125.8 (28.9) <0.001Σ
SBP by 60 s (% baseline) 109.5 (8.2) 97.6 (6.6) 86.6 (11.5) <0.001Σ
SBP by 90 s (mmHg) 142.9 (23.3) 135.3 (23.0) 127.3 (30.0) <0.001Σ
SBP by 90 s (% baseline) 109.9 (8.8) 98.7 (7.1) 87.7 (13.0) <0.001Σ
SBP by 110 s (mmHg) 143.2 (23.5) 135.3 (22.8) 126.5 (30.7) <0.001Σ
SBP by 110 s (% baseline) 110.1 (9.1) 98.7 (7.1) 87.1 (13.6) <0.001Σ
Diastolic blood pressure (DBP)
Baseline DBP (mmHg) 70.7 (10.4) 74.0 (10.7) 76.4 (13.1) <0.001Σ
Δ DBP (mmHg) −18.5 (7.8) −26.4 (7.5) −37.5 (9.7) <0.001Σ
Nadir DBP (mmHg) 52.2 (12.3) 47.5 (12.8) 38.9 (14.6) <0.001Σ
DBP by 30 s (mmHg) 75.6 (11.6) 72.3 (12.2) 66.0 (16.0) <0.001Σ
DBP by 90 s (mmHg) 75.9 (11.3) 73.1 (11.7) 68.3 (15.2) <0.001Σ
DBP by 90 s (mmHg) 75.7 (11.0) 73.3 (11.6) 68.6 (15.6) <0.001Σ
DBP by 110 s (mmHg) 75.8 (11.3) 73.1 (11.5) 68.0 (15.7) <0.001Σ
Heart rate (HR)
Baseline HR (bpm) 66.4 (10.0) 65.3 (10.0) 63.1 (10.0) <0.001Σ
Δ HR (bpm) 20.6 (8.6) 19.8 (8.8) 18.4 (9.5) <0.001Σ
Nadir HR (bpm) 87.0 (12.6) 85.1 (13.1) 81.5 (14.2) <0.001Σ
HR by 30 s (bpm) 72.6 (11.4) 72.2 (11.8) 69.7 (12.2) <0.001Σ
HR by 60 s (bpm) 74.1 (11.4) 74.1 (11.5) 71.8 (12.2) <0.001Σ
HR by 90 s (bpm) 73.1 (10.9) 73.1 (11.2) 71.0 (11.9) 0.001Σ
HR by 110 s (bpm) 73.1 (10.9) 73.2 (11.1) 71.0 (11.9) 0.001Σ
Orthostatic intolerance and blackouts/faints
OI symptoms during active stand (%) 33.1 39.4 44.9 <0.001χt
Ever had a blackout or fainted (%) 17.8 20.2 21.6 0.07χt
Demographics
Age 61.2 (8.1) 61.2 (8.1) 63.6 (9.0) <0.001Σ
Age range 50 - 89 50 - 90 50 - 91 -
Female gender (%) 48.8 53.4 64.4 <0.001χt
Medications
Polypharmacy (5 or more meds) (%) 16.7 16.8 21.0 0.02χt
On cardiac glycosides (e.g. digoxin) (C01A) (%) 0.8 0.8 0.5 0.76χt
On antiarrhythmics class I and III (C01B) (%) 0.2 0.4 0.4 0.58χt
On beta-blocker (C07A) (%) 10.4 10.4 15.7 <0.001χt
On diuretic (C03) (%) 6.2 5.7 6.5 0.66χt
On ACE-i (C09A) (%) 10.1 10.9 9.7 0.58χt
Romero-Ortuno et al. BMC Geriatrics 2013, 13:73 Page 7 of 14
http://www.biomedcentral.com/1471-2318/13/73
Table 2 MOH clusters characterisation (Continued)
On ARA (C09C) (%) 7.8 6.8 7.2 0.48χt
On calcium channel blocker – with mainly vascular effects (C08C) (%) 7.3 7.3 6.4 0.66χt
On calcium channel blocker – with direct cardiac effects (C08D) (%) 1.0 1.3 1.5 0.44χt
On peripherally acting anti-adrenergic (e.g. alpha-blocker) (C02C) (%) 0.7 1.8 2.3 0.004χt
On cardiac vasodilator (e.g. nitrates) (C01D) (%) 1.0 1.2 1.7 0.35χt
On peripheral vasodilator (C04A) (%) 0.2 0.2 0.3 0.92χt
On antiepileptic (N03A) (%) 1.8 2.5 2.4 0.33χt
On antipsychotic (N05A) (%) 0.8 0.9 1.8 0.07χt
On anxiolytics (N05B) (%) 1.2 1.6 2.7 0.03χt
On hypnotics or sedatives (N05C) (%) 3.4 3.3 4.4 0.36χt
On antidepressant (N06A) (%) 4.0 5.7 10.2 <0.001χt
Comorbidities
Hypertension (%) 32.1 32.4 35.3 0.25χt
Angina (%) 4.3 3.9 5.9 0.07χt
Heart attack (%) 4.3 3.9 3.3 0.51χt
Heart failure (%) 0.7 0.9 0.6 0.59χt
Diabetes (%) 7.4 6.1 5.9 0.21χt
Stroke (%) 1.2 1.1 1.3 0.89χt
TIA (%) 1.3 1.7 1.7 0.56χt
Abnormal heart rhythm (%) 6.5 7.4 7.3 0.61χt
Parkinson’s disease (%) 0.1 0.4 0.5 0.13χt
3 or more chronic diseases (%) 23.2 23.7 26.9 0.13χt
Disability
Any IADL disability (%) 3.2 3.8 5.2 0.06χt
Cognition
MMSE score 28.6 (2.0) 28.7 (1.7) 28.6 (1.6) 0.18Σ
Σ Spearman’s rank correlation coefficient; χt Chi-squared test for trend.
Romero-Ortuno et al. BMC Geriatrics 2013, 13:73 Page 8 of 14
http://www.biomedcentral.com/1471-2318/13/73studies have focused on sex-related differences in OI
[53,54]. As regards the age effect, a previous study inves-
tigating the changing face of orthostatic and neuro-
cardiogenic syncope with age found that symptomatic
patients were significantly younger than asymptomatic
[55], which is in keeping with our results.
Although the age and sex effects are non-modifiable,
they could be relevant in terms of the postulated sequence
of pathophysiological steps (OH → OI → fainting). In
short, female and older participants were more likely to
have an MOH-3 pattern (Table 3); however, when OI was
the dependent variable and MOH-3 membership a covari-
ate, being female and older were significantly less likely to
have OI (Table 4). And when MOH-3 and OI were
included in a model with blackouts or faints as the
dependent variable, being female was once again signifi-
cantly associated with increased risk (Table 5). The differ-
ential effects of age and sex are difficult to explain in our
cross-sectional design. However, in terms of the age effect,
it is plausible that advancing age may lead to animpairment of both the orthostatic hemodynamic re-
sponse (i.e. more MOH-3) and the awareness of the latter
(i.e. less OI). Indeed, we know that awareness of ortho-
static hypotension is influenced by age: in younger sub-
jects it is usually brief but symptomatic whereas in older
individuals the situation is reversed [56,57].
In terms of the differential effects of sex in the patho-
physiological sequence OH→ OI→ fainting, it is difficult
to explain why women had more MOH-3, more history of
faints, but less OI. OI is much more common in young
women relative to men, children or older women [58,59],
and women in our sample were middle-aged and older.
Another possibility is the presence of sex differences in
the self-report of OI; for example, a previous study showed
that symptoms of vertigo, dizziness or unsteadiness may
be more related to psychological factors in men [60]. The
full understanding of this sex effects requires purpose-
designed research.
According to our full sample results, OI is more likely
to be reported by more co-morbid and disabled patients
Figure 2 MOH phenotypes (visual description of SBP, DBP and HR behaviour).
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prudent to avoid the use of hypnotics and sedatives. In-
deed, hypnotics and sedatives may add to the OI effect of
MOH-3, and this is consistent with previous observations
on the reduced tolerability of benzodiazepines in the eld-
erly [61] and the greater incidence of OI in older subjects
taking sedatives and hypnotics [62]. In keeping with thelatter, and consistently in meta-analyses and systematic re-
views, the use of sedatives and hypnotics, antidepressants,
and benzodiazepines has been shown to be significantly
associated with falls in older individuals [63,64].
People with history of faints or blackouts may suffer from
conditions not directly related to OH such as epilepsy or
cardiac syncope (hence the association with anti-epileptics
Table 3 Generalised linear model to predict MOH-3 membership
Full sample B Std. error P Odds ratio 95% wald confidence interval for odds ratio
Lower Upper
Female sex 0.55 0.08 <0.001 1.73 1.46 2.04
C07A (beta blockers) 0.47 0.12 <0.001 1.60 1.26 2.04
C08C (peripheral CCB) −0.38 0.16 <0.001 0.68 0.49 0.94
N06A (antidepressants) 0.69 0.14 <0.001 1.99 1.50 2.64
Heart attack −0.47 0.23 0.042 0.62 0.40 0.98
age 0.03 0.00 <0.001 1.03 1.03 1.04
Subsample ≥70 years old B Std. error P Odds ratio 95% wald confidence interval for odds ratio
Lower Upper
Female sex 0.34 0.17 0.040 1.41 1.02 1.96
C07A (beta blockers) 0.44 0.19 0.021 1.55 1.07 2.25
C08C (peripheral CCB) −0.60 0.27 0.025 0.55 0.33 0.93
N06A (antidepressants) 0.70 0.30 0.018 2.01 1.13 3.60
Diabetes −0.62 0.33 0.064 0.54 0.28 1.04
Age 0.05 0.02 0.009 1.05 1.01 1.09
Dependent variable: MOH type 3 (large drop, under-recovery). Binary logistic response, forward conditional procedure. Predictors entered: female sex,
polypharmacy, C01A (cardiac glycosides), C01B (antiarrhythmics), C07A (beta blockers), C03 (diuretics), C09A (ACE-i), C09C (ARA), C08C (peripheral CCB), C08D
(cardiac CCB), C02C (alpha blockers), C01D (cardiac vasodilators), C04A (peripheral vasodilators), N03A (antiepileptics), N05A (antipsychotics), N05B (anxiolytics),
N05C (hypnotics, sedatives), N06A (antidepressants), hypertension, angina, heart attack, heart failure, diabetes, stroke¸ TIA, abnormal heart rhythm, Parkinson’s
disease, three or more chronic diseases, any IADL disability, age.
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samples, polypharmacy (i.e. being on five or more regular
medications) was independently associated with history of
blackouts or faints. We know that age-related physiologic
impairments of heart rate, blood pressure, baroreflex sen-
sitivity, and cerebral blood flow, in combination with a
higher prevalence of comorbid disorders and concomitantTable 4 Contribution of MOH-3 towards OI in the presence of
Full sample B Std. error P
MOH-3 0.39 0.08 <0.001
Female sex −0.17 0.06 0.008
N05C (hypnotics, sedatives) 0.60 0.17 <0.001
Heart attack 0.47 0.16 0.004
3 or more chronic diseases 0.18 0.08 0.023
Any IADL disability 0.32 0.16 0.048
Age −0.02 0.00 <0.001
MMSE −0.04 0.02 0.043
Subsample ≥70 years old B Std. error P
C08C (peripheral CCB) −0.53 0.22 0.015
N03A (antiepileptics) 0.91 0.44 0.036
3 or more chronic diseases 0.38 0.15 0.011
Dependent variable: phasic OI. Binary logistic response, forward conditional proced
C01B (antiarrhythmics), C07A (beta blockers), C03 (diuretics), C09A (ACE-i), C09C (AR
(cardiac vasodilators), C04A (peripheral vasodilators), N03A (antiepileptics), N05A (an
(antidepressants), hypertension, angina, heart attack, heart failure, diabetes, stroke¸
diseases, any IADL disability, age, MOH-3, MMSE.medications (including polypharmacy), account for the in-
creased susceptibility of older persons to syncope [65].
In the full sample, phasic OI was more common in
those with history of faints or blackouts, suggesting that
part of the latter syndrome may be of hemodynamic na-
ture [66]. Interestingly, faints or blackouts were not sig-
nificantly related to MOH-3, which supports previouspotential confounders
Odds ratio 95% wald confidence interval for odds ratio
Lower Upper
1.47 1.25 1.73
0.84 0.74 0.96
1.83 1.31 2.54
1.59 1.16 2.19
1.19 1.02 1.39
1.38 1.00 1.90
0.98 0.98 0.99
0.96 0.93 1.00
Odds ratio 95% wald confidence interval for odds ratio
Lower Upper
0.59 0.39 0.90
2.50 1.06 5.86
1.46 1.09 1.95
ure. Predictors entered: female sex, polypharmacy, C01A (cardiac glycosides),
A), C08C (peripheral CCB), C08D (cardiac CCB), C02C (alpha blockers), C01D
tipsychotics), N05B (anxiolytics), N05C (hypnotics, sedatives), N06A
TIA, abnormal heart rhythm, Parkinson’s disease, three or more chronic
Table 5 Contribution of MOH-3 and OI towards history of blackout or faints in the presence of potential confounders
Full sample B Std. error P Odds ratio 95% wald confidence interval for odds ratio
Lower Upper
OI 0.24 0.08 0.003 1.27 1.09 1.48
Female sex 0.30 0.08 <0.001 1.35 1.16 1.57
Polypharmacy 0.32 0.10 0.002 1.37 1.12 1.68
N03A (antiepileptics) 0.87 0.21 <0.001 2.39 1.57 3.63
N06A (antidepressants) 0.48 0.14 0.001 1.62 1.22 2.15
Transient Ischemic Attack 0.66 0.26 0.013 1.93 1.15 3.25
Abnormal heart rhythm 0.67 0.13 <0.001 1.95 1.49 2.53
Age −0.01 0.00 0.013 0.99 0.98 1.00
Subsample ≥70 years old B Std. error P Odds ratio 95% wald confidence interval for odds ratio
Lower Upper
Female sex 0.45 0.19 0.014 1.58 1.10 2.26
Polypharmacy 0.42 0.19 0.028 1.52 1.05 2.20
N03A (antiepileptics) 1.57 0.45 <0.001 4.82 2.00 11.61
Abnormal heart rhythm 0.84 0.24 <0.001 2.31 1.45 3.67
Dependent variable: Ever had a blackout or fainted. Binary logistic response, forward conditional procedure. Predictors entered: female sex, polypharmacy, C01A
(cardiac glycosides), C01B (antiarrhythmics), C07A (beta blockers), C03 (diuretics), C09A (ACE-i), C09C (ARA), C08C (peripheral CCB), C08D (cardiac CCB), C02C
(alpha blockers), C01D (cardiac vasodilators), C04A (peripheral vasodilators), N03A (antiepileptics), N05A (antipsychotics), N05B (anxiolytics), N05C (hypnotics,
sedatives), N06A (antidepressants), hypertension, angina, heart attack, heart failure, diabetes, stroke¸ TIA, abnormal heart rhythm, Parkinson’s disease, three or
more chronic diseases, any IADL disability, age, MOH-3, MMSE, OI.
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much more strongly with endpoint clinical events such
as (pre-)syncope, blackouts and recurrent unexplained
falls than does OH (i.e. the isolated blood pressure drop
sign) per se [20,21]. Indeed, it would appear that the
above-mentioned three pathophysiological steps (OH →
OI → fainting) operate as a chain, so the prevention of
endpoint clinical events could be tackled both at im-
proving OH hemodynamics and at minimising OI as a
mediator [21]. We know that fall preventive interven-
tions should be provided to older people by a structured,
multifaceted approach [67].
As in the previous pilot MOH investigation [25], there
was an increasing gradient in baseline SBP across clusters,
but only MOH-3 had a mean baseline SBP in the hyper-
tension range (i.e. ≥ 140 mmHg). Indeed, MOH-3 re-
sembles the syndrome of supine hypertension–orthostatic
hypotension (SH-OH), as applied to beat-to-beat ortho-
static blood pressure data. We agree with previous recom-
mendations that, of all patients with SH‐OH, those who
have OI require the most clinical attention [7]. In patients
with SH-OH, the avoidance of medications that may
exacerbate OH and OI and the judicious use of antihy-
pertensive classes that are less likely to aggravate pos-
tural blood pressure changes may be safe and adequate
approaches to the treatment of this challenging condi-
tion [68].
Interestingly, antihypertensive types that have shown
consistent benefits in the treatment of hypertension in the
very elderly (e.g. ACE-i and diuretics, as in the HYVETtrial [69,70]) were not linked with any of our adverse out-
comes (i.e. MOH-3, OI, history of faints). Several other
studies (e.g. SYST-EUR, CONVINCE, VALUE) have dem-
onstrated the benefits of treating aged hypertensive pa-
tients with cardiovascular medications that were not
associated with adverse outcomes (e.g. angiotensin recep-
tor antagonists), or seemed even protective (i.e. peripheral
CCB) in our study [71]. A Cochrane systematic review
established that treating healthy older persons with hyper-
tension is highly efficacious, and that benefits of treatment
with low dose diuretics or beta-blockers were clear for
persons in their 60s to 70s with either diastolic or systolic
hypertension [72]. However, this Cochrane review con-
cluded that differential treatment effects based on patient
risk factors, pre-existing cardiovascular disease and com-
peting co-morbidities could not be established from the
published trial data [72]. Our study sheds light into the lat-
ter limitation and supports the overall conclusion that, in
treating older and frailer hypertensive patients, the evi-
dence of benefit does not necessarily have to conflict with
the evidence of potential harm.
A number of limitations in this study must be noted.
Firstly, its observational cross-sectional design precludes
the inference of causality relationships and direct ex-
trapolation of associations. As we stated above, results
are to be interpreted with caution and represent ‘in-
sights’ rather than confirmed signals.
Secondly, despite the large total sample size, we know
that the 38% of participants who did not have a Health
Centre assessment were more likely to have lower socio-
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were weaker (handgrip strength) and slower (walking
speed) than Health Centre respondents [31]. In addition,
as Table 1 showed, participants who attended the Health
Centre assessment but had no MOH data were older, more
hypertensive, more medicated, and more comorbid and
disabled than those whose active stand data were included.
For these reasons, the frailest in the population may have
been underrepresented in the analytic sample. Precise in-
formation as to what made participants not complete each
stage of the participants’ flow chart (Figure 1) is not avail-
able, but frailty-related reasons are very likely. It is known
that frailty is associated with missing data in research
designs that involve the collection of physical performance
measures (i.e. as required in the active stand) [73].
The statistical techniques employed in our analyses
also have limitations. Indeed, the K-means cluster ana-
lysis is exploratory in nature, and the scale and variabil-
ity of the clustering variables may affect results in
unstandardised analyses [74]. However, we replicated
here the exact same K-means clustering method as pre-
viously conducted in a different, smaller and convenient
sample [25], leading to very similar results in terms of
the characterisation of the MOH clusters. Hence, it is
plausible that these three MOH groups exist ‘out there’
in clinical practice, although naturally we cannot con-
firm their existence as a true group structure. There is
ongoing work in TILDA in this area.
As stated above, some of the results from the logistic
regression models should be interpreted with caution
due to the nature of how the multivariate logistic models
were developed, and especially due to the presence of a
large number of covariates in the models. In addition,
only few participants were on medications potentially as-
sociated to MOH-3 such as peripheral vasodilators or
antiarrhythmics, so results for the latter classes may have
been underpowered.
A limitation of the active stand protocol is that infor-
mation was lacking on precise dosages, time of ingestion
of, and compliance with, the reported medications. Even
though polypharmacy was used as a control variable in
all models, specific drug interactions towards the out-
comes of interest could not be investigated. Limitations
of the active stand test itself include its known diurnal
variability and relationship with meals [1].
Finally, a limitation of the present study is the impact
of frailty on orthostatic hemodynamic responses, OI and
faints/blackouts. Given that the latter are complex disor-
ders involving multiple physiological systems, the inclu-
sion of frailty may have complemented the inclusion of
comorbidity, disability and cognition in the models. For
example, older adults without measured hypertension,
who are not on an anti-hypertensive medication, appear
to have high physiological reserve in general [75].Unsurprisingly then, many of the people with OH have
other many health deficits as well, which can combine to
make the person frail and when frailty is taken into
account, the specific influence of OH on risk is greatly
attenuated, even becoming no longer statistically signifi-
cant [76]. This is an important area of ongoing work in
the longitudinal dimension of TILDA.Conclusions
In the present study, we replicated our previously
proposed morphological classification of orthostatic
hypotension (MOH, intended for beat-to-beat monitor-
ing) in the first wave of The Irish Longitudinal Study on
Ageing, and we found that the clinical associations were
similar as previously reported (e.g. association with OI)
[25]. In addition, we proposed the MOH-3 pattern as a
beat-to-beat analogue of SH-OH and studied its associa-
tions with cardiovascular and neurological medications,
concurrent OI, and history of fainting.
Our findings offer cross-sectional insights that, if fur-
ther validated, may inform the development of clinical
guidelines for the treatment of SH-OH. Based on the re-
sults of the current study, in a typical clinical setting
using phasic orthostatic blood pressure measurements,
MOH-3 should be recognised by the presence of base-
line hypertension (>140 mmHg), an initial orthostatic
blood pressure drop greater than 40 mmHg, and failure
to recover 90% of the baseline blood pressure after 2
minutes of standing. If a patient fulfilling those criteria
has complaints of OI, then his/her risk of (pre-)syncope,
falls and blackouts is higher and clinicians should avoid
(if possible) medications that may exacerbate OH and
OI (such as beta blockers, antidepressants and hypnotics
and sedatives), and make a judicious use of antihyper-
tensives that are less likely to aggravate postural blood
pressure changes. Naturally, this should be done within
a wider multifaceted approach.
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